Novo Nordisk (NVO) Stock: Company Begins Trial Testing Lower Doses of Wegovy Pill

TLDR

• Novo Nordisk has started a new clinical trial testing lower doses of its Wegovy weight-loss pill
• The 450-patient study began August 12 and runs until 2028, testing two undisclosed low doses against a placebo
• The current lowest starter dose is 1.5mg, with patients able to work up to 25mg
• Wegovy pill sales hit $500 million in Q2 2026, up from $350 million in Q1
• The pill has been prescribed more than 5 million times since its U.S. launch in January 2026

Novo Nordisk (NVO) is running a new clinical trial to find the lowest dose of its Wegovy weight-loss pill that still helps patients shed weight. NVO stock was up 1.47% at the time of reporting.

Novo Nordisk A/S, NVO

The study enrolled 450 overweight patients and kicked off on August 12. It will run through 2028 and is comparing two low, undisclosed doses of the pill against a placebo.

Patients in the trial must have a BMI of at least 27, which falls into the World Health Organization’s overweight category. The company has not disclosed what the exact doses being tested are.

… Continue reading the full article at the original source below.